Lornamead Inc. – FDA 483, Apr 11, 2023
Lornamead Inc., a drug manufacturer in Tonawanda, NY, was inspected and cited for significant deficiencies across multiple areas. These include failures in raw material identity testing, inadequate complaint handling for adverse events, insufficient investigations into out-of-specification results, lack of proper temperature control for storage, and non-adherence to procedures for managing rejected drug products. The observations indicate a need for comprehensive improvements in their quality control and manufacturing processes.
ID · 666c43d8-a9c9-4ade-81ed-5d1800823a16
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.